ImmunityBio releases data on Anktiva for non-small cell lung cancer

immunitybio-releases-data-on-anktiva-for-non-small-cell-lung-cancer
Medical and Healthcare. Woman doctor touching a hologram of cancer lung.

pada smith/iStock via Getty Images

  • ImmunityBio (IBRX) has released positive data on its IL-15 receptor agonist Anktiva (nogapendekin alfa inbakicept) in combination with a checkpoint inhibitor for non-small cell lung cancer.
  • One study examined Anktiva + a checkpoint inhibitor, such as Keytruda (pembrolizumab) and Opdivo (nivolumab), as a first-line treatment for NSCLC. Data showed